Literature DB >> 21871449

Focal adhesion protein abnormalities in myelodysplastic mesenchymal stromal cells.

Carmen Mariana Aanei1, Florin Zugun Eloae, Pascale Flandrin-Gresta, Emmanuelle Tavernier, Eugen Carasevici, Denis Guyotat, Lydia Campos.   

Abstract

Direct cell-cell contact between haematopoietic progenitor cells (HPCs) and their cellular microenvironment is essential to maintain 'stemness'. In cancer biology, focal adhesion (FA) proteins are involved in survival signal transduction in a wide variety of human tumours. To define the role of FA proteins in the haematopoietic microenvironment of myelodysplastic syndromes (MDS), CD73-positive mesenchymal stromal cells (MSCs) were immunostained for paxillin, pFAK [Y(397)], and HSP90α/β and p130CAS, and analysed for reactivity, intensity and cellular localisation. Immunofluorescence microscopy allowed us to identify qualitative and quantitative differences, and subcellular localisation analysis revealed that in pathological MSCs, paxillin, pFAK [Y(397)], and HSP90α/β formed nuclear molecular complexes. Increased expression of paxillin, pFAK [Y(397)], and HSP90α/β and enhanced nuclear co-localisation of these proteins correlated with a consistent proliferative advantage in MSCs from patients with refractory anaemia with excess blasts (RAEB) and negatively impacted clonogenicity of HPCs. These results suggest that signalling via FA proteins could be implicated in HPC-MSC interactions. Further, because FAK is an HSP90α/β client protein, these results suggest the utility of HSP90α/β inhibition as a target for adjuvant therapy for myelodysplasia.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21871449     DOI: 10.1016/j.yexcr.2011.08.007

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  15 in total

Review 1.  The bone-marrow niche in MDS and MGUS: implications for AML and MM.

Authors:  Irene M Ghobrial; Alexandre Detappe; Kenneth C Anderson; David P Steensma
Journal:  Nat Rev Clin Oncol       Date:  2018-01-09       Impact factor: 66.675

2.  Mesenchymal stromal cells from patients with myelodyplastic syndrome display distinct functional alterations that are modulated by lenalidomide.

Authors:  Ruben A Ferrer; Manja Wobus; Catrin List; Rebekka Wehner; Claudia Schönefeldt; Barbara Brocard; Brigitte Mohr; Martina Rauner; Marc Schmitz; Maik Stiehler; Gerhard Ehninger; Lorenz C Hofbauer; Martin Bornhäuser; Uwe Platzbecker
Journal:  Haematologica       Date:  2013-05-28       Impact factor: 9.941

3.  Down-regulation of Dicer1 promotes cellular senescence and decreases the differentiation and stem cell-supporting capacities of mesenchymal stromal cells in patients with myelodysplastic syndrome.

Authors:  Youshan Zhao; Dong Wu; Chengming Fei; Juan Guo; Shuncheng Gu; Yang Zhu; Feng Xu; Zheng Zhang; Lingyun Wu; Xiao Li; Chunkang Chang
Journal:  Haematologica       Date:  2014-10-31       Impact factor: 9.941

Review 4.  Myelodysplastic syndromes: revisiting the role of the bone marrow microenvironment in disease pathogenesis.

Authors:  Marc H G P Raaijmakers
Journal:  Int J Hematol       Date:  2012-01-06       Impact factor: 2.490

5.  Serine protease inhibitor kunitz-type 2 is downregulated in myelodysplastic syndromes and modulates cell-cell adhesion.

Authors:  Fernanda Marconi Roversi; Matheus Rodrigues Lopes; João Agostinho Machado-Neto; Ana Leda F Longhini; Adriana da Silva Santos Duarte; Mariana Ozello Baratti; Bruna Palodetto; Flávia Adolfo Corrocher; Fernando Vieira Pericole; Paula de Melo Campos; Patricia Favaro; Fabiola Traina; Sara Teresinha Olalla Saad
Journal:  Stem Cells Dev       Date:  2014-02-18       Impact factor: 3.272

6.  Defective proliferative potential of MSCs from pediatric myelodysplastic syndrome patients is associated with cell senescence.

Authors:  Qinghua Liu; Hongbo Zhu; Jing Dong; Helou Li; Hong Zhang
Journal:  Int J Clin Exp Pathol       Date:  2015-10-01

Review 7.  Mesenchymal stem cells in immune-mediated bone marrow failure syndromes.

Authors:  Maria-Christina Kastrinaki; Konstantia Pavlaki; Aristea K Batsali; Elisavet Kouvidi; Irene Mavroudi; Charalampos Pontikoglou; Helen A Papadaki
Journal:  Clin Dev Immunol       Date:  2013-12-10

Review 8.  Bone Marrow Immunity and Myelodysplasia.

Authors:  Claude Lambert; Yuenv Wu; Carmen Aanei
Journal:  Front Oncol       Date:  2016-07-20       Impact factor: 6.244

9.  The functional interplay of transcription factors and cell adhesion molecules in experimental myelodysplasia including hematopoietic stem progenitor compartment.

Authors:  Suchismita Daw; Sujata Law
Journal:  Mol Cell Biochem       Date:  2020-10-04       Impact factor: 3.396

10.  PTK2 and PTPN11 expression in myelodysplastic syndromes.

Authors:  Mariana Lazarini; João Agostinho Machado-Neto; Leticia Fröhlich Archangelo; Bruna Fernandes Mendes-Silva; Carolina Louzão Bigarella; Fabiola Traina; Sara Teresinha Olalla Saad
Journal:  Clinics (Sao Paulo)       Date:  2013-10       Impact factor: 2.365

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.